New Covid-19 vaccine approved.
In a scenario where several pharmaceutical companies aim to offer their Covid-19 vaccine in Colombia, new trials have begun in the country.
It is the INO-4800 vaccine, which has already begun its phase 3 studies in the country. The vaccine is produced by Inovio, an American biotechnology company dedicated to the production of DNA drugs. The company’s products focus on trying to protect the population from infectious agents, such as cancer.
The National Institute for Food and Drug Surveillance (Invima) in Colombia has approved the initiation of these clinical trials. With this, the vaccine will go to clinical trials that would allow its application in humans and subsequently its approval.
This type of trial is already pending approval in countries such as the Philippines, Brazil and Mexico. The vaccine involves the use of two doses with an interval of about a month, like many other vaccines, in individuals over 1
“INOVIO is pleased to share the news of the regulatory authorization to proceed with our Phase 3 trial in Colombia. With COVID-19 infection rates on the rise in many areas and with still limited access to vaccines in many countries around the world, we thank health authorities for supporting our efforts to make more vaccines available and accessible. If approved, the INO-4800 DNA vaccine candidate can further enhance vaccination in Colombia and other countries, as it can serve as a first-line or booster vaccine. ” This was stated by the president and CEO of the Inovio company, Dr. J. Joseph Kim.
It is worth mentioning that this vaccine does not need to be refrigerated in its first year. This is because it is based on nucleic acids (DNA). Thus the vaccine is stable in its first year at room temperature. In addition, it has an expected life of five years at normal refrigeration temperature.
In this same sense, according to the company, the new vaccine does not need to be frozen for its transport and storage.
With Inovo, 5 pharmaceutical companies are already carrying out their clinical trials in the country, which would allow us to expand the offer of biologics.